MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:Whether testing for MET  exon 14 status should be standard of careParallel vs sequential testing by DNA-based vs RNA-based NGSCo-occurring driver mutations in patients with METex14 mutation–positive NSCLCOptimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapyEMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinibPresenters:Luis Paz-Ares, MD, PhD Medical OncologyUniversity Hospital Doce de OctubreMadrid, SpainD. Ross Camidge, MD, PhDProfessor of Medicine/OncologyUniversity of Colorado Cancer CenterAurora, ColoradoKaren L. Reckamp, MD, MSProfessor of MedicineDirector, Division of Medical OncologyDepartment of MedicineCedars SinaiLos Angeles, CaliforniaLink to full program, including associated downloadable slidesets:  https://bit.ly/2ExadCf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.